Yousif Capital Management LLC Purchases 20,690 Shares of Sanofi (NASDAQ:SNY)

Yousif Capital Management LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 53.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 59,611 shares of the company’s stock after purchasing an additional 20,690 shares during the period. Yousif Capital Management LLC’s holdings in Sanofi were worth $2,875,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. abrdn plc grew its stake in shares of Sanofi by 25.6% in the 4th quarter. abrdn plc now owns 314,180 shares of the company’s stock worth $15,153,000 after buying an additional 64,095 shares during the last quarter. Avantra Family Wealth Inc. bought a new position in Sanofi in the 4th quarter worth about $673,000. DAVENPORT & Co LLC increased its stake in Sanofi by 40.7% during the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after purchasing an additional 664,455 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Sanofi by 13.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 63,845 shares of the company’s stock worth $3,079,000 after buying an additional 7,615 shares during the last quarter. Finally, Keudell Morrison Wealth Management lifted its stake in shares of Sanofi by 1.7% in the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock worth $624,000 after buying an additional 217 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Sanofi currently has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Stock Up 0.9 %

Shares of NASDAQ SNY opened at $53.35 on Monday. The stock has a market capitalization of $135.39 billion, a price-to-earnings ratio of 21.43, a P/E/G ratio of 0.99 and a beta of 0.57. The firm’s 50-day moving average price is $49.72 and its 200-day moving average price is $52.39. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The company has a current ratio of 1.46, a quick ratio of 0.74 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. On average, equities research analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.